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Individuals in areas of intense malaria transmission exhibit resistance (or tolerance) to levels of parasitemia
in their blood that would normally be associated with febrile illness in malaria-naïve subjects. The resulting
level of parasitemia associated with illness (the pyrogenic threshold) is highest in childhood and lowest in
adulthood. Clinical parallels between malarial and bacterial endotoxin tolerance have led to the supposition
that both share common physiological processes, with nitric oxide (NO) proposed as a candidate mediator. The
hypotheses that NO mediates tolerance and blood stage parasite killing in vivo were tested by determining its
relationship to age and parasitemia cross-sectionally and longitudinally in a population of 195 children and
adults from Papua New Guinea encountering intense malaria exposure. Despite pharmacological clearance of
asymptomatic parasitemia, NO production and mononuclear cell NO synthase (NOS) activity were remarkably
stable within individuals over time, were not influenced by parasitemia, and varied little with age. These results
contrast with previous smaller cross-sectional studies. Baseline NO production and NOS activity did not
protect against recurrent parasitemia, consistent with previous data suggesting that NO does not have
antiparasitic effects against blood stage infection in vivo. The NO indices studied were markedly higher in
specimens from study subjects than in samples from Australian controls, and NOS activity was significantly
associated with plasma immunoglobulin E levels, consistent with induction of NO by chronic exposure to other
infections and/or host genetic factors. These results suggest that NO is unlikely to mediate killing of blood
stage parasites in this setting and is unlikely to be the primary mediator in the acquisition or maintenance of
malarial tolerance.
The paroxysmal fever of human malaria is thought to result
from induction of endogenous pyrogens such as tumor necrosis
factor alpha and interleukin-1 by a parasite toxin (or toxins)
released at the time of schizont rupture (22). Yet residents of
regions where malaria is highly endemic (such as the northern
coast of Papua New Guinea [PNG]) experience relatively few
episodes of symptomatic malaria (19), despite an estimated
inoculation rate of greater than one infective bite per day (13).
Chronic asymptomatic parasitization appears to be common in
regions where malaria is highly endemic (12), and levels of
parasitemia (31, 38, 41) reportedly exceed those associated
with fever in malaria-naïve subjects (21). These observations
have led to the proposal that a form of antitoxic immunity to
malaria exists that has been termed tolerance, a condition that
enables the host to resist the pyrogenic effects of a malaria
toxin(s) (17, 32). It has been shown that the threshold of
peripheral parasitemia associated with febrile illness can be
sharply defined in regions of intense malaria transmission (6,
38, 42) and that this threshold has a striking exponentially
decaying relationship with increasing age, from a peak at 1 year
of age to a plateau in adulthood (19, 38, 41). In contrast,
antiparasitic immune responses (thought to be responsible for
lowering parasite densities and therefore the risk of clinical
malaria) are generally assumed to increase with advancing age.
Malarial tolerance shares interesting parallels with the well-
established phenomenon of bacterial endotoxin tolerance,
which has led to the proposition that they are mediated by an
ultimately common cellular pathway (18). Repeated injections
of endotoxin result in diminishing fever responses in humans
over a short period of time (45), and it has been shown that
even a first malaria infection can induce cross-tolerance to
endotoxin (23, 40). The biological mediator nitric oxide (NO)
has been proposed to mediate endotoxin tolerance in experi-
mental models (49) and has been shown to down-regulate
endotoxin-induced increases in tumor necrosis factor alpha in
animal studies (25) and in human monocytes (47). Further-
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more, clinical and genetic association studies have suggested
that NO production can protect against severe malaria (2, 24).
Strikingly high basal production of NO has been described in
disease-free individuals from areas where malaria is endemic
(3, 9), and NO levels were reportedly higher in children than
adults in one uncontrolled PNG study (17). NO levels were
positively correlated with parasitemia in two of these studies
(3, 9), consistent with data from animal models (26) and the
demonstration that the putative malarial toxin glycosylphos-
phatidylinositol can induce NO synthase (NOS) in macrophage
and endothelial cells (44).
Hence, we and others (18) have hypothesized that NO is a
key mediator of malarial tolerance in heavily exposed individ-
uals and that NO levels would positively correlate with para-
sitemia and inversely correlate with age in parallel with the
decaying pyrogenic threshold. To test these propositions, we
studied NO production and NOS activity in an asymptomatic
malaria-exposed population ranging in age from 1 to 60 years,
in whom disease-related inflammatory responses would not
confound interpretation of the data. NO donors have been
shown to kill blood stage malaria parasites in vitro (37), and it
has been suggested that NO may have similar antiparasitic
effects in vivo (10, 37). We therefore extended our studies to
investigate whether NO production would be inversely related
to parasitemia (the opposite of our primary hypothesis) and
whether NO indices would predict the likelihood of recurrent
parasitemia after pharmacological clearance. We also studied
the relationship between NO and baseline plasma immuno-
globulin E (IgE) levels (a marker of intestinal parasitosis), as it
has been suggested that IgE-mediated induction of NOS2 via
CD23 may increase NO in populations where malaria is en-
demic (34).
MATERIALS AND METHODS
Subjects and controls. The ethics committees of the PNG Institute of Medical
Research and the Menzies School of Health Research approved the study.
Subjects were recruited from two coastal villages (Haven and Midiba) in Madang
Province, PNG, during the high-transmission wet season between February and
May 2000 (14). In this region, four species of malaria that are transmittable to
humans are present, the inoculation rate is estimated at one infective bite per day
(13), there is little seasonal variation in parasitemia rates (16), and malaria is
characterized by relatively mild attacks that decrease in frequency with age (19).
Controls were non-malaria-exposed asymptomatic adults from Darwin in tropi-
cal north Australia with little exposure to intestinal parasites (20).
Nonpregnant adults and children aged 1 years were screened by fingerprick
blood smear for entry into the study. Subjects were selectively enrolled (at time
point T0) to include balanced numbers of microscopically parasitemic and apara-
sitemic subjects. Exclusion criteria were as follows: fever (axillary temperature,
37.5°C) on any of three occasions within 24 h, antimalarial or nonsteroidal
anti-inflammatory drug ingestion (including aspirin) within 1 week, history of
recent malaria infection (fever, chills, sweats, headache, or myalgia within 1
week), or diarrhea (as gastroenteritis has been associated with increased NO
production) (29). Darwin controls were recruited in February 2002 with the same
criteria, except axillary temperatures were recorded only twice, 16 h apart, and
controls were not followed up. Subjects with Plasmodium falciparum infection
alone or in combination with other species received a single dose of 25 mg of
sulfadoxine/kg of body weight and 1.25 mg of pyrimethamine (Roche, Basel,
Switzerland)/kg of body weight and subjects with Plasmodium vivax, Plasmodium
malariae, and/or Plasmodium ovale infection were given three daily doses of 10
mg base of chloroquine phosphate (Pharmamed, Zejtun, Malta)/kg of body
weight. Follow-up was done using the same procedures approximately 2 to 4
weeks after enrollment at T1 and again approximately 7 weeks after initial
enrollment at T2.
Specimen collection and processing. Blood smears were stained with 4%
Giemsa stain and examined and/or cross-checked by two field microscopists with
12 years of experience). Negative smears had no parasites seen in 100 high-
power (magnification, 1,000) oil-immersion fields. Subjects and controls were
given a low-nitrate meal of chicken and rice (and low-nitrate water) and then
fasted for 12 h overnight to control for the effect of dietary nitrates on NO
measurement (1). Adherence to the fasting protocol was confirmed by supervi-
sion (PNG) or questionnaire (Darwin). A second-void urine was collected after
the fast, analyzed for infection by dipstick and/or microscopy, and then stored
with isopropanol (20% final volume). Blood was collected by venipuncture,
plasma was separated by centrifugation, and then peripheral blood mononuclear
cells (PBMC) were removed by density centrifugation. Manual leukocyte counts
were done with whole blood to calculate parasite densities (27), and all samples
were stored at 70°C until assays were carried out.
Laboratory assays. Combined readings from two blood smears, taken 24 h
apart at screening or venipuncture, were used to categorize the parasite species
present and to account for periodic fluctuation of parasitemia (12). Systemic NO
production (nitrate plus nitrite [NOx]) was measured in urine and plasma with
Aspergillus nitrate reductase coupled with the Griess reaction (1). Creatinine
(Cr) and plasma IgE were measured with an automated analyzer. Urine NOx
excretion was expressed as the ratio of NOx/Cr to control for variations in urine
concentration. The percentage of urinary fractional excretion of NOx (FENOx)
was calculated thus: FENOx  100  (urine NOx/plasma NOx)/(urine Cr/plasma
Cr). NOS activity in lysates of unstimulated PBMC pellets was measured as the
amount of [14C]arginine that was converted to citrulline per milligram of total
cellular protein/hour (46). P. falciparum merozoite surface protein 1 and P. vivax
apical membrane antigen 1 were detected by PCR (to assess treatment efficacy)
in whole blood spotted onto filter paper as previously described (43).
Statistical methods. Statistical analysis was performed with Stata 7.0 software
(StataCorp, College Station, Tex.). Summary statistics are presented in accor-
dance with the distribution of the data (i.e., means with standard deviations or
medians with interquartile ranges [IQR]). Pairwise comparisons of nonparamet-
ric continuous data were performed with the Mann-Whitney U test. Otherwise,
nonparametric data were logarithmically transformed to normality in the case of
plasma NOx, urine NOx/urine Cr, and PBMC NOS activity or considered in
ordered quintiles in the case of the highly skewed parasite densities and plasma
IgE levels. Correlations were performed after transformation by comparing
Pearson’s r against a value of 0. Multivariate analyses of continuous data were
done using linear regression, and logistic regression was used to compute the
odds of parasite recurrence in subjects whose parasitemia was initially cleared by
treatment. Analysis of variance for repeated measures was used to examine
within-subject variation in continuous measures over time, and paired Wilcoxon
tests were used to analyze changes in NO production with clearance or recur-
rence of parasitemia. P values of 0.05 were considered to indicate statistical
significance.
RESULTS
Baseline characteristics. Single blood smears from 424 in-
dividuals aged 1 year (62% from Midiba; 48% male) were
screened by microscopy to enable selection of subjects for
enrollment. As a reflection of prevalence at the population
level, the proportion of subjects positive for any malaria par-
asite at screening was highest in the 5- to 9-year-old age group
and for P. falciparum in the 1- to 4-year-old age group (Fig.
1A). The age-related prevalence of parasitemia, splenomegaly
(83% in subjects aged 14 years, with a peak of 92% in
children 5 to 9 years old), and stated bed-net use (86% overall;
98% in children 1 to 4 years old) was broadly consistent with
previous data reported from this region (16, 19). There were
195 subjects enrolled into the study (median age, 14 years;
IQR, 9 to 25; 62% from Midiba) (Table 1). The mean age of
the 22 Darwin controls was 35 years (standard deviation, 8),
and 41% were male. Venisection failed at T0 in 17 subjects
(rain washed out the collection with 16 subjects) and 4 subjects
failed to produce a urine sample. Two blood smears taken on
consecutive days were available for examination from each of
178 subjects.
Additional parasite species were found in the second smear
for 20 (28%) of 71 initially aparasitemic subjects and in 25
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(24%) of 106 initially parasitemic subjects. As anticipated, the
relationship between level of parasitemia and age was best
modeled as an inverse exponential function, both for all par-
asites (R  0.54; P  0.0005) and for parasitemia with P.
falciparum (R  0.46; P  0.0005) (Fig. 1B). Axillary temper-
ature was recorded on all three occasions within 24 h in 77, 71,
and 73% of subjects at T0, T1, and T2, respectively, with all
subjects having at least one temperature recording at each time
point. All five of the subjects who were febrile (axillary tem-
perature  37.5°C) at T1 or T2 also reported concurrent symp-
toms of illness; therefore, subjects with less than three readings
who were not febrile on those occasions and who were well
were not excluded from the analysis. Eleven of the enrolled
subjects met exclusion criteria at T1, and 7 met the criteria at
T2 (2 subjects met the criteria at both time points); these
subjects were excluded from statistical analyses involving data
collected at those times.
Plasma Cr was normally distributed in subjects who were
18 years, and none of these children or adolescents had a
plasma Cr above the midpoint of their age-standardized ref-
erence range (as used by the Royal Darwin Hospital) (data not
shown). These low values are likely due to low lean body mass,
since 95% of these subjects’ weight was less than their median
age-standardized weight (28) (data not shown). Plasma Cr was
also normally distributed in subjects of19 years, and only two
men had a plasma Cr above the normal range of 60 to 120
mol/liter (Cr was 125 mol/liter in both men). The median
FENOx was 34% in children and adolescents, 34% in adults,
and 33% in Darwin controls.
Pharmacological clearance of parasitemia and follow-up.
Follow-up at T1 was successful for 174 (89%) of the 195 en-
rolled subjects after a median of 14 days (range, 12 to 32 days).
Of these subjects, 132 (76%) were studied on the 14th day and
22 (13%) were studied on the 28th day. Those leaving the study
did not significantly differ in age, sex, or village of origin from
the remaining subjects. Follow-up at T2 was not attempted
with all subjects for logistical reasons: follow-up was successful
in 94 (92%) of 102 intended cases after a median of 56 days
from T0 (range 40 to 77). Antimalarial treatment was given to
all but 3 of 135 initially parasitemic eligible subjects at T0. It
was successful in 106 (86%) of the 123 subjects (with any
parasite) who attended follow-up at T1 and in 82 (86%) of the
95 subjects whose baseline parasitemia included P. falciparum.
PCR was performed with specimens from the 100 nonex-
cluded subjects at T1 who had been judged aparasitemic by
microscopic examination of samples and who had been given
treatment to eradicate parasitemia at T0. In samples from 99
subjects with PCR results, P. falciparum infection was evident
in only 3 (3%) and P. vivax in 1 (1%). We studied 65 subjects
at T2 who had been given treatment to eradicate parasitemia at
T0 and who were aparasitemic by microscopic sample exami-
nation at T1. Parasitemia recurred in 29 (48%) of these sub-
jects after a median of 42 days (IQR, 30 to 44) from T1, with
P. falciparum present in 14 (48%) and P. vivax in 18 (63%) of
subjects. As expected, the odds of recurrence of parasitemia at
T2 after confirmed clearance at T1 was inversely related to age
(odds ratio  0.5 for successive age group; 95% confidence
interval [CI]  0.3 to 0.7; P  0.001) and positively related to
the time elapsing between T1 and T2 (odds ratio 1.5 for each
successive week; 95% CI  1.2 2.0; P  0.001). There were
51 subjects who had P. falciparum infection at T0 in whom
parasitemia was cleared with treatment at T1; P. falciparum
was present in 10 (20%) of these subjects at T2. Thus, the
efficacy of parasite clearance and the nature of its subsequent
recurrence in some subjects were deemed to be appropriate for
the purpose of relating measures of NO to parasitemia in this
study.
Basal NO production at T0 and its relationship to age. The
median plasma NOx was 37 mol/liter (IQR, 25 to 55) in 178
FIG. 1. A. Blood smear results in 424 subjects from Papua New
Guinea who were screened for enrollment into the study. Results
represent the reading of a single daily smear. (B) Parasite density of P.
falciparum in 105 enrolled subjects at baseline. Diamonds signify the
higher of two measurements taken 24 h apart.
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subjects for whom plasma was available and was significantly
higher in each age group than in Darwin controls (Fig. 2). Age
only explained 2.5% of the overall variation in plasma NOx in
PNG subjects (P  0.033), and plasma NOx was predicted to
fall by 3.5% every 5 years, from a peak of 41 mol/liter at age
2 to 31 mol/liter at age 40. Basal PBMC NOS activity in 158
subjects for whom a sample was available (median, 1,030 pmol/
mg; IQR, 670 to 1540; 20 samples were lost during transport)
varied even less by age group than did plasma NOx. NOS
activity was not significantly related to age or sex but was
significantly higher in PNG subjects than in Darwin controls
(median, 613 pmol/mg; IQR, 495 to 899; P  0.003). PBMC
NOS activity and plasma NOx were not significantly correlated.
Urine NOx/urine Cr ratios appeared to decrease significantly
across successive age groups from a peak in early childhood to
a low in adulthood (r2  0.35; P  0.001). However, this result
was almost certainly due to a progressive growth-related in-
crease in the denominator (urine Cr) used to calculate this
ratio (5). When 24-h NOx excretion was estimated by adjusting
urine NOx/urine Cr ratio in children and adolescents by
weight-standardized 24-h urine Cr excretion values (36), this
apparent significant decrease disappeared (data not shown).
Relationship between indices of NO and parasitemia. There
was no significant difference in plasma NOx or PBMC NOS
activity between subjects with malaria parasitemia (including
all species) and aparasitemic subjects at T0 in univariate anal-
yses or after adjustment for age group and/or sex. Likewise,
there was no difference in any measure of NO production
between subjects with P. falciparum parasitemia on blood
smear and those without (i.e., including aparasitemic subjects
and those with parasites other than P. falciparum) or those with
P. falciparum parasitemia and aparasitemic subjects. There was
no relationship between the highest recorded density of para-
sitemia over 2 consecutive days (all parasites) or density of P.
falciparum parasitemia and any measure of NO production
cross-sectionally at T0. Similarly, there was no significant rela-
tionship between the level of parasitemia on the day of veni-
section and any measure of NO production.
There was a high level of consistency in the central tenden-
cies and spread of results between T0, T1, and T2 for all mea-
sured indices of NO production. Within individuals, there was
no significant change between results taken at two or more
time points for nonexcluded subjects in plasma NOx, urine
NOx/urine Cr, or PBMC NOS activity (P  0.20 in each anal-
ysis of variance for repeated measures). This longitudinal sta-
bility in NO indices was also evident upon clearance or recur-
rence of parasitemia following successful initial treatment
(Table 2). Basal plasma NOx and PBMC NOS activity at T0
were not significantly predictive of recurrent parasitemia, ei-
ther in a univariate analysis or after controlling for the signif-
icant effects of age and elapsed time (data not shown).
FIG. 2. Plasma NOx levels in Darwin controls (DC) and PNG
subjects not excluded at T0. The median plasma NOx level in Darwin
controls (11 mol/liter; IQR, 7 to 24) was significantly lower than for
each age group of PNG subjects (P  0.001 for each pairwise com-
parison; Mann-Whitney U test). In the PNG group, age only explained
2.5% of the overall variation in plasma NOx levels (P  0.033), with
the predicted NOx level falling 3.5% for every 5 years of increasing
age. The horizontal lines in the middle of the boxes represents the
median, and the boxes extend from the 25th to the 75th percentile.
Whiskers extend no further than the most distant data point or 1.5
times the IQR. Outlying values are represented by dots.
TABLE 1. Baseline characteristics of parasitemias in subjects included in the statistical analysisa
Age group
(yr) n
%
Male
Parasitemia Negative
(%) No. (%) of Pf
b Pf/lc (95% CI) Parasites/lc (95% CI)
Pf Pf, Pv Pf, Pm Pf, Pv, Pm Pf, Pv, Po Pv Pv, Pm Pm Po
1–4 22 32 11 3 0 0 0 3 0 0 0 5 (23) 14 (64) 1,008 (403–2520) 1,267 (623–2577)
5–9 38 53 15 7 3 2 0 4 0 1 0 6 (16) 27 (57) 429 (219–839) 453 (267–780)
10–14 39 51 11 6 4 1 1 4 2 3 0 7 (18) 23 (33) 323 (176–592) 259 (156–430)
15–19 23 39 11 2 1 1 1 0 0 0 0 7 (30) 16 (70) 163 (90–295) 191 (111–327)
20 73 45 21 3 0 1 0 9 2 1 1 35 (48) 25 (34) 107 (68–168) 95 (69–132)
Total 195 46 69 21 8 5 2 20 4 5 1 60 (31) 105 (54) 280 (207–379) 262 (202–339)
a Number of subjects with each species (or combined species) of parasite on examination of two consecutive daily blood smears. Pf, P. falciparum: Pv, P. vivax; Pm,
P. malariae; Po, P. ovale; Negative, negative for parasites. Shown are results for 195 subjects who did not meet the exclusion criteria at T0, so that the parasitemias given
are reflective of those found in asymptomatic individuals.
b Number and percentage of subjects with P. falciparum parasitemia either as the sole infecting parasite or in combination with other parasites.
c Geometric mean of the highest-density P. falciparum parasitemia and the highest densities of combined species (Parasites/l) measured from two consecutive daily
blood smears. Note that there is some overlap between the last two columns, which are not mutually exclusive.
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Relationship between NO production and IgE. Baseline
plasma IgE ranged from 35 to 18,400 international units (kU)/
liter and was highly skewed (mean, 3,606; median, 2,200; IQR,
1,000 to 4,800). IgE levels increased with age to a peak in the
10- to 14-year-old group before decreasing and leveling out in
subjects aged 15 years and older. IgE was significantly predic-
tive of PBMC NOS activity but explained only 4% of the
overall variance (P  0.014). Predicted NOS activity was 9%
higher in successive quintiles of IgE (95% CI  2 to 17) and
not effected by age or sex. There was no association between
IgE levels and the measures of systemic NO metabolites. IgE
levels were not associated with the presence or density of
malaria parasitemia in general or of P. falciparum in particular.
DISCUSSION
We studied NO production and NOS activity in a population
of children and adults exposed to intense malaria transmission
and demonstrated no relationship with parasitemia and little
change with advancing age. This pattern contrasts sharply with
that of the exponentially decaying age relationship of the py-
rogenic threshold and argues against NO being a major medi-
ator of malarial tolerance. All indices of NO measurement
were remarkably stable within individuals over time, regardless
of the elimination or recurrence of malaria parasitemia. Nev-
ertheless, NO production was much higher in the study sub-
jects from rural PNG than in urban adult controls from north-
ern Australia. Few subject specimens showed evidence of
parasitemia on PCR after drug treatment, which minimizes the
likelihood that widespread drug resistance, combined with a
(low) parasitemic threshold effect for NO production, con-
founded the results. There was no evidence that differences in
renal handling of NO metabolites affected results, since sub-
jects were healthy, had normal renal function, and had FENOx
levels similar to those of controls.
The reasons for increased basal NO production in malaria-
exposed populations are unclear but may include tropical en-
teropathy (29) and/or intestinal parasitosis. We observed a
modest association between extraordinarily high levels of IgE
(as a surrogate marker of parasitic infection) and PBMC NOS
activity, in accordance with previous studies using NO metab-
olites (34, 35). That this relationship was not stronger might
reflect a requirement for complexed IgE to optimally activate
the CD23 pathway (33) or a contribution of other pathways
linking intestinal parasitosis and tropical enteropathy to NO
production. It appears from the disassociation of plasma NOx
and NOS activity in this study and a previous smaller study (9)
that cellular sources other than PBMC may be responsible for
elevated NO production. These may include liver, spleen, mus-
cle, gut, and the endothelium of other tissues; these have been
associated with NOS2 activation in animal and human malaria
and bacterial infections (18). It is possible that malaria and
other infections and/or influences have contributed to selection
for genetic polymorphisms favoring NOS2 activation in indi-
viduals living in PNG (24), although we have not detected
common NOS2 polymorphisms in these subjects (8).
That malaria parasitemia was not associated with NO pro-
duction in the present study, but was in previous smaller cross-
sectional studies in Tanzanian children (3) and adults from
Papua Province, Indonesia (9), is difficult to explain; factors
may include statistical chance, classification of parasitemia
(only one smear was examined in a previous study) (3), the
epidemiology of nonmalarial infections influencing NO, and/or
genetic polymorphisms in NOS2 or other regulatory cytokine
genes. For example, a genetically determined maximal level of
NO production may have been reached in Madang residents in
response to nonmalarial stimuli, such that augmentation by
malaria infection was not evident. The longitudinal stability of
NOS activity and NO production and lack of protection against
recurrent parasitemia support the preponderance of murine
data (4) and previous human genetic association studies (24)
that suggest NO does not mediate killing of blood stage par-
asites in vivo, at least in the malaria-tolerant state. These data
also argue against NO being a likely candidate for the mediator
of density-dependent regulation (10), a phenomenon first de-
scribed in a Madang cohort (11).
Attention should now refocus on alternative biological path-
ways that may mediate malarial tolerance, given that it seems
unlikely that NO or antibodies to the proposed malaria toxin
glycosylphosphatidylinositol (7) are primarily involved. Al-
though earlier studies implicated the importance of NO to
endotoxin tolerance development (49), recent work using
NOS2 knockout mice has shown that NO is dispensable to this
process (48). Experimental evidence is converging to suggest
that differential activation of toll-like receptor 2 (by malarial
toxin) and toll-like receptor 4 (by bacterial endotoxin) can
result in cross-tolerance, independent of paracrine mediators
such as NO (15, 30, 39). This accords well with the earlier in
vivo experimental data from human studies (23, 40). It is im-
portant to note that our findings in asymptomatic individuals
do not necessarily exclude other potential antitoxic or anticy-
TABLE 2. Longitudinal analysis of effect of clearance or recurrence
of parasitemiaa
Parameter Value Median change (IQR)b Pc
Clearance of malaria
parasitemia (all species)
Plasma NOx (mmol/liter) 90 1.2 (9.4 to 13.6) 0.37
PBMC NOS activity
(pmol/mg)
80 9.9 (55.9 to 56.6) 0.94
Clearance of P. falciparum
specifically
Plasma NOx (mmol/liter) 70 0.03 (11.1 to 11.9) 0.98
PBMC NOS activity
(pmol/mg)
61 14 (56.7 to 51.8) 0.55
Recurrence of malaria
parasitemia (all species)
Plasma NOx (mmol/liter) 26 1.1 (16.1 to 20.4) 0.77
PBMC NOS activity
(pmol/mg)
25 37.1 (66.8 to 57.6) 0.65
Recurrence of P. falciparum
specifically
Plasma NOx (mmol/liter) 11 6.2 (13.6 to 29.5) 0.37
PBMC NOS activity
(pmol/mg)
11 53.1 (271 to 57.1) 0.42
a Subjects were given treatment to eradicate parasitemia at study point T0 and
who were aparasitemic at T1.
b Median change (IQR) in parameters between T0 and T1 for clearance of
parasitemia and T1 and T2 for recurrence.
c Significance of paired Wilcoxon test.
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toadherence roles for NO, particularly in malaria disease states
where there is supportive evidence in both animal models (4)
and human clinical studies (2, 24). The findings do, however,
suggest that investigative efforts should be directed toward
other mechanisms if tolerance-like immunity is to be induced
as a novel form of therapy or vaccination for malaria.
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